ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
ALXO on Nasdaq
Shares outstanding
53,136,600
Price per share
$1.11
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
27,785,299
Total reported value
$51,273,440
% of total 13F portfolios
0%
Share change
-1,286,146
Value change
+$2,395,861
Number of holders
60
Price from insider filings
$1.11
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 8.5% $2,042,240 4,641,455 Redmile Group, LLC 30 Jun 2025
HBM Healthcare Investments (Cayman) Ltd. 8.4% +27% $2,295,000 +$547,266 4,500,000 +31% HBM Healthcare Investments (Cayman) Ltd. 31 Mar 2025
TANG CAPITAL PARTNERS LP 6.3% $1,681,410 3,296,883 TANG CAPITAL MANAGEMENT, LLC 31 Dec 2024
MILLENNIUM MANAGEMENT LLC 6% +18% $5,706,871 +$861,071 3,188,196 +18% Millennium Management LLC 17 Oct 2025
FMR LLC 3.4% $917,426 1,798,875 FMR LLC 29 Nov 2024

As of 30 Sep 2025, 60 institutional investors reported holding 27,785,299 shares of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO). This represents 52% of the company’s total 53,136,600 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) together control 51% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
venBio Partners LLC 18% 9,699,925 0% 10% $17,750,863
Redmile Group, LLC 6.3% 3,332,983 -1.7% 0.59% $6,099,359
MILLENNIUM MANAGEMENT LLC 4.9% 2,622,861 +432% 0% $4,799,836
Almitas Capital LLC 4.8% 2,536,891 -0.06% 1.1% $4,642,511
VANGUARD GROUP INC 2.9% 1,528,619 -4.5% 0% $2,797,372
ACADIAN ASSET MANAGEMENT LLC 2.3% 1,220,825 -3.7% 0% $2,233,000
Driehaus Capital Management LLC 1.5% 795,777 0.01% $1,456,272
TWO SIGMA ADVISERS, LP 1.4% 719,800 +2.3% 0% $1,317,234
AMERIPRISE FINANCIAL INC 1.2% 652,897 0% $1,194,802
TWO SIGMA INVESTMENTS, LP 1.1% 606,671 +27% 0% $1,110,208
BANK OF AMERICA CORP /DE/ 1% 530,828 -49% 0% $971,415
Privium Fund Management B.V. 0.96% 509,059 0% 0.17% $931,578
BANK OF MONTREAL /CAN/ 0.89% 474,781 -29% 0% $868,849
BlackRock, Inc. 0.84% 447,692 -37% 0% $819,277
GEODE CAPITAL MANAGEMENT, LLC 0.66% 352,335 +12% 0% $645,030
JANE STREET GROUP, LLC 0.34% 180,416 -11% 0% $330,161
UBS Group AG 0.32% 172,570 -40% 0% $315,803
RENAISSANCE TECHNOLOGIES LLC 0.31% 164,499 +93% 0% $301,033
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.21% 113,063 -31% 0% $206,905
STATE STREET CORP 0.21% 111,928 -9.9% 0% $204,828
BANK OF NOVA SCOTIA 0.2% 105,858 0% 0% $193,720
NORTHERN TRUST CORP 0.18% 95,160 -30% 0% $174,143
IEQ CAPITAL, LLC 0.17% 92,233 0% $168,786
GSA CAPITAL PARTNERS LLP 0.17% 88,165 +8.4% 0.01% $161,000
MORGAN STANLEY 0.16% 85,290 -27% 0% $156,081

Institutional Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 39,098 $42,281 -$87 $1.11 2
2025 Q3 27,785,299 $51,273,440 +$2,395,861 $1.83 60
2025 Q2 29,030,607 $12,060,366 -$2,784,536 $0.42 58
2025 Q1 34,764,459 $21,657,278 -$4,297,920 $0.62 83
2024 Q4 41,028,903 $68,515,761 -$8,509,648 $1.67 85
2024 Q3 45,458,855 $83,126,108 -$40,248,836 $1.82 90
2024 Q2 48,509,608 $292,389,850 -$2,826,841 $6.03 107
2024 Q1 45,776,694 $510,423,087 -$5,822,832 $11.15 105
2023 Q4 45,764,823 $681,456,826 +$185,269,081 $14.89 93
2023 Q3 33,283,050 $159,762,120 -$6,348,070 $4.80 75
2023 Q2 34,283,564 $257,462,824 -$6,376,897 $7.51 74
2023 Q1 35,697,467 $161,353,578 -$6,004,481 $4.52 85
2022 Q4 36,433,730 $410,607,954 -$2,049,707 $11.27 85
2022 Q3 36,439,308 $348,724,761 +$5,422,376 $9.57 96
2022 Q2 35,930,829 $290,675,201 -$16,579,357 $8.09 92
2022 Q1 36,794,716 $621,886,079 +$2,845,527 $16.90 94
2021 Q4 36,290,670 $779,906,251 -$55,903,331 $21.49 103
2021 Q3 34,508,619 $2,548,791,083 +$109,794,972 $73.86 113
2021 Q2 33,314,685 $1,821,610,718 -$28,517,807 $54.68 102
2021 Q1 33,493,682 $2,466,083,905 +$80,496,245 $73.74 90
2020 Q4 32,294,048 $2,779,048,270 +$439,356,967 $86.20 89
2020 Q3 27,250,196 $1,027,708,220 +$1,027,708,220 $37.74 56